Jaume Mora

25.4k total citations · 1 hit paper
216 papers, 5.5k citations indexed

About

Jaume Mora is a scholar working on Neurology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jaume Mora has authored 216 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Neurology, 79 papers in Molecular Biology and 47 papers in Cancer Research. Recurrent topics in Jaume Mora's work include Neuroblastoma Research and Treatments (96 papers), Cancer, Hypoxia, and Metabolism (39 papers) and Sarcoma Diagnosis and Treatment (26 papers). Jaume Mora is often cited by papers focused on Neuroblastoma Research and Treatments (96 papers), Cancer, Hypoxia, and Metabolism (39 papers) and Sarcoma Diagnosis and Treatment (26 papers). Jaume Mora collaborates with scholars based in Spain, United States and Canada. Jaume Mora's co-authors include William L. Gerald, Carmen de Torres, Nai‐Kong V. Cheung, Manel Esteller, Carlos Cordon‐Cardo, Cinzia Lavarino, David Polsky, Ximena Opitz-Araya, Scott W. Lowe and Paola Capodieci and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Jaume Mora

205 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

2001 769 citations Jaume Mora et al. profile →

Peers

Countries citing papers authored by Jaume Mora

Since Specialization

Citations

This map shows the geographic impact of Jaume Mora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Mora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Mora more than expected).

Fields of papers citing papers by Jaume Mora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaume Mora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Mora. The network helps show where Jaume Mora may publish in the future.

Co-authorship network of co-authors of Jaume Mora

This figure shows the co-authorship network connecting the top 25 collaborators of Jaume Mora. A scholar is included among the top collaborators of Jaume Mora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaume Mora. Jaume Mora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma 2025 ·Cancer Research ·(unknown), (unknown), Enrique Blanco, (unknown), (unknown), Guerau Fernández, Soledad Gómez‐González, Oscar Muñoz, (unknown), Sara Pérez‐Jaume, Marta García, (unknown), Silvia Mateo‐Lozano, Nicolò Riggi, Alexandra Avgustinova, Cinzia Lavarino, Luciano Di Croce, Sara Sánchez-Molina, Jaume Mora	1
2	Human EWS-FLI protein levels and neomorphic functions show a complex, function-specific dose–response relationship in Drosophila 2024 ·Open Biology ·(unknown), Cristina Molnar, (unknown), José Reina, Salud Llamazares, (unknown), Jaume Mora, Cayetano González	2
3	Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma. 2024 ·Journal of Clinical Oncology ·Jaume Mora, Godfrey Chi Fung Chan, Daniel A. Morgenstern, Loredana Amoroso, Karsten Nysom, Joerg Faber, Arthur Wingerter, (unknown), (unknown), James Eldridge, Karen Tornøe, Maria Düring, Brian H. Kushner	2
4	Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma 2023 ·Biochemical Pharmacology ·Guillem Pascual‐Pasto, (unknown), Helena Castillo‐Ecija, (unknown), (unknown), Mònica Vilà-Ubach, (unknown), (unknown), (unknown), Nagore G. Olaciregui, (unknown), Sara Pérez‐Jaume, Enrique de Álava, Òscar M. Tirado, Cinzia Lavarino, Jaume Mora, Ángel M. Carcaboso	7
5	Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes 2023 ·Cancers ·Juan Pablo Muñoz, (unknown), (unknown), Sara Pérez‐Jaume, (unknown), (unknown), (unknown), (unknown), (unknown), Moira Garraus, (unknown), Jaume Mora	13
6	The onset of PI3K‐related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib 2022 ·EMBO Molecular Medicine ·(unknown), (unknown), (unknown), Leonor Gouveia, Ana Angulo‐Urarte, Laia Muixí, (unknown), (unknown), Nagore G. Olaciregui, Lucía Fanlo, Anna Esteve‐Codina, Cinzia Lavarino, Biola M. Javierre, Verónica Celis, (unknown), Susana López‐Fernández, Eulàlia Baselga, Jaume Mora, Sandra D. Castillo, Mariona Graupera	35
7	Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1 2022 ·Oncogene ·Daniel J. García-Domínguez, Nabil Hajji, Roser López‐Alemany, Sara Sánchez-Molina, (unknown), (unknown), Santiago Rello‐Varona, Eduardo Andrés‐León, Adrián Benito, Hector C. Keun, Jaume Mora, Òscar M. Tirado, Enrique de Álava, Lourdes Hontecillas‐Prieto	17
8	Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies 2022 ·Cancers ·Sara Sánchez-Molina, (unknown), Víctor Sánchez‐Margalet, Luis de la Cruz‐Merino, Jaume Mora, Enrique de Álava, Daniel J. García-Domínguez, Lourdes Hontecillas‐Prieto	6
9	Functional neuroimaging in nonepileptiform electroencephalographic patterns in status epilepticus 2021 ·Acta Neurologica Scandinavica ·Albert Muñoz‐Vendrell, (unknown), (unknown), (unknown), (unknown), Jaume Mora, Mercè Falip	2
10	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells 2020 ·Nature Communications ·Marta Martínez-Lage, Raúl Torres, (unknown), (unknown), M. Cruz Martín, Francisco Moya, Óscar Quintana-Bustamante, Susana García‐Silva, Ángel M. Carcaboso, Paolo Petazzi, Clara Bueno, Jaume Mora, Héctor Peinado, José C. Segovia, Pablo Menéndez, Sandra Rodríguez	79
11	Both Epimutations and Chromosome Aberrations Affect Multiple Imprinted Loci in Aggressive Wilms Tumors 2020 ·Cancers ·Laura Pignata, Orazio Palumbo, Flavia Cerrato, (unknown), Enrique de Álava, Josep Roma, Soledad Gallego, Jaume Mora, Massimo Carella, Andrea Riccio, Gaetano Verde	7
12	Optimizing the storage of chemotherapeutics for ophthalmic oncology: stability of topotecan solution for intravitreal injection 2020 ·Ophthalmic Genetics ·(unknown), (unknown), (unknown), (unknown), (unknown), Helena Castillo‐Ecija, Jaume Català‐Mora, Jaume Mora, Paula Schaiquevich, Guillermo Chantada, Ángel M. Carcaboso	5
13	Tissue Compatibility of SN‐38‐Loaded Anticancer Nanofiber Matrices 2018 ·Advanced Healthcare Materials ·(unknown), (unknown), Gaia Botteri, Helena Castillo‐Ecija, Guillem Pascual‐Pasto, F. Cano, (unknown), (unknown), (unknown), Manuel Vázquez‐Carrera, Mariona Suñol, Jaume Mora, José Antonio Tornero, Alejandro Sosnik, Ángel M. Carcaboso	5
14	Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier 2017 ·Journal of Controlled Release ·Guillem Pascual‐Pasto, Nagore G. Olaciregui, Javier A.W. Opezzo, Helena Castillo‐Ecija, (unknown), Sonia Paco, (unknown), Mònica Vilà-Ubach, (unknown), Montserrat Torrebadell, Mariona Suñol, Paula Schaiquevich, Jaume Mora, Guillermo F. Bramuglia, Guillermo Chantada, Ángel M. Carcaboso	8
15	SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery 2015 ·Biomaterials ·(unknown), Guillem Pascual‐Pasto, Francisco Cano, Mònica Vilà-Ubach, (unknown), Paula Schaiquevich, José Antonio Tornero, Alejandro Sosnik, Jaume Mora, Ángel M. Carcaboso	39
16	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma 2012 ·Clinical Cancer Research ·Idoia García, (unknown), José Ríos, Gema Doménech, Nai‐Kong V. Cheung, André Oberthuer, Matthias Fischer, John M. Maris, Garrett M. Brodeur, Barbara Hero, Eva Rodríguez, Mariona Suñol, Patricia Galván, Carmen de Torres, Jaume Mora, Cinzia Lavarino	51
17	Refractory nonconvulsive status epilepticus in Creutzfeldt‐Jakob disease 2010 ·Epileptic Disorders ·(unknown), Mercè Falip, (unknown), Jordi Bruna, Antoni Palasí, Luisa Corral, (unknown), Susana Boluda, Jaume Mora, Álex Iranzo, Carmen Serrano	14
18	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature 2010 ·Clinical Cancer Research ·Katleen De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Eggert, Matthias Fischer, Isabelle Janoueix‐Lerosey, Cinzia Lavarino, John M. Maris, Jaume Mora, Akira Nakagawara, André Oberthuer, Miki Ohira, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, Jo Vandesompele	65
19	Topical Mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma 2002 ·Jaume Mora, (unknown)	17
20	Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring 1996 ·American Journal of Veterinary Research ·J. J. Aramayona, Jaume Mora, Lorenzo Fraile, Maria Alice Amorim Garcia, (unknown), (unknown)	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact